Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource (225 pages)

Edition: 1st ed.

ISBN: 1-68108-805-3

Content: The coronavirus disease 2019 (COVID-19) outbreak has spread throughout the globe and much time has passed since it was declared as a pandemic by the World Health Organization (WHO). COVID-19: Diagnosis and Management provides clinicians and scholars all the information on this disease in 2 volumes. Readers will find a concise and visual reference for this viral disease and will be equipped with the knowledge to assess and manage Sar-Cov-2 infection cases in clinical settings. This book is divided into two parts (I and II). Part I provides comprehensive information about 1 History of Coronaviruses, 2 Epidemiology of COVID-19, 3 Clinical presentation of this viral disease and 4 COVID-19 diagnosis. Part II covers broader topics about this communicable disease including 1 the prevention and treatment methodology, 2 mortality and long-term complications, 3 COVID-19 vaccines and future perspectives. Key Features: - Covers all the aspects of COVID-19 making this a perfect textbook for virology and medical students. -Chapter wise description and segregation of topics from pathophysiology to diagnosis and management of COVID-19. -Six chapters in the first part which focus on clinical basics of COVID-19. -Six chapters in the second part which cover broader topics for practical infection control. -Multiple tables and figures which summarize and highlight important points. -Presents a summary of the current standards for the evaluation and diagnosis of COVID-19. - Features a detailed list of references, abbreviations, and symbols. This book is an essential textbook reference for medical students, scientists (virologists, pulmonologists) and public health officials who are required to understand COVDI-19 diagnosis and management as part of their clinical training or professional work.

Note: Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Prevention of COVID-19: Facts to Overcome the Myths -- Rajesh Kumar1, Mangesh Pradeep Kulkarni1, Sheetu Wadhwa1 and Soundappan Kathirvel2,* -- INTRODUCTION -- MEASURES TO PREVENT THE SPREAD, ASSOCIATED MYTHS AND FACTS -- Personal Protective Equipment (PPE) -- Head Covers -- Face Shield -- Mask -- Goggles -- Gloves -- Shoe Covers -- Gowns or Coveralls -- SANITIZATION AND DISINFECTION -- Hand Hygiene -- For Public -- Prevention of COVID-19 Among Frontline Healthcare Workers -- Cleaning of Vegetables-Fruits -- Safe Handling of Currency and Paper Documents -- Cough or Respiratory Etiquettes -- Precautions to be Taken While Coughing/Sneezing or Any Physical Contact -- Spitting or Littering in Public -- Disinfection of Public Places -- Disposal and Disinfection of PPEs -- WATER TREATMENT AND WASTE MANAGEMENT -- Management of Water and Faecal Waste -- Safety of Water Supplies -- SOCIAL MEASURES -- Physical Distancing -- Quarantine and Isolation -- Home Quarantine -- Institutional Quarantine -- Staff Guidelines -- Utility Guidelines -- Lockdown and Travel Restrictions -- Zonal Classification of the Geography -- PROPHYLAXIS FOR COVID-19 -- Dietary Recommendations for the Prevention of COVID-19 -- General Measures -- Medicinal Plant Measures/Procedures -- Medical Prophylaxis for Healthcare Workers and Contacts of a Positive Patient -- REGULAR SCREENING -- PRECAUTIONS FOR TRAVEL -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Current Treatment Methods for Coronavirus Disease-19 -- Kuldeep Kumar1, Sonal1, Pankaj Bhatia1, Dhandeep Singh1, Amteshwar S. Jaggi1 and Nirmal Singh1,* -- INTRODUCTION -- OVERVIEW OF VARIOUS TREATMENT STRATEGIES FOR COVID-19. , Hydroxychloroquine -- HCQ in Treatment of COVID-19 -- Remdesivir -- Remdesivir in Treatment of COVID-19 -- Lopinavir/Ritonavir -- Lopinavir/Ritonavir in Treatment of COVID-19 -- Favipiravir -- Favipiravir in Treatment of COVID-19 -- Azithromycin (AZ) -- AZ in COVID-19 Treatment -- Arbidol -- Arbidol in Treatment of COVID-19 -- Ribavirin -- Ribavirin in COVID-19 Treatment -- Teicoplanin -- Teicoplanin in COVID-19 Treatment -- Ivermectin -- Ivermectin in Treatment of COVID-19 -- Nitazoxanide -- Nitazoxanide in COVID-19 Treatment -- Corticosteroids -- Corticosteroids in the Treatment of COVID-19 -- Immuno Modulating Agents-Interferons (IFN's) -- IFN's in Treatment of COVID-19 -- Monoclonal Antibody Therapy -- 80R Immunoglobulin G1 (IgGI) -- CR3014 -- Monoclonal Antibody Therapy in COVID-19 Treatment -- Tocilizumab -- Sarilumab -- Limitations and Suggestions Regarding mAb's -- Triple Therapy -- Miscellaneous Drugs -- Herbal Drugs for COVID-19 -- Glycyrrhizin -- Glycyrrhizin in COVID-19 -- Hesperetin -- Baicalin -- Scutellarin -- Plasma Therapy -- Plasma Therapy in the Treatment of COVID-19 -- Potential of Stem Cell Therapy in COVID-19 -- BCG Vaccine -- VARIOUS REGULATORY GUIDELINES GIVEN BY NIH (NATIONAL INSTITUTE OF HEALTH) FOR TREATMENT OF COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- AUTHORS CONTRIBUTION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Mortality -- Rimesh Pal1 and Sanjay Kumar Bhadada1,* -- INTRODUCTION -- REPRESENTING MORTALITY - MORTALITY RATE VS. CASE-FATALITY RATE -- FALLACIES IN ESTIMATING MORTALITY USING CASE-FATALITY RATE -- REPORTING COVID-19-RELATED DEATHS -- COMPARING CASE-FATALITY RATES OF COVID-19 WITH OTHER RELATED VIRAL DISEASES -- COMPARING COVID-19 CASE-FATALITY RATES AMONG VARIOUS NATIONS -- CAUSES OF DEATH IN COVID-19. , PARAMETERS PREDICTING MORTALITY IN COVID-19 -- Clinical Parameters -- Age -- Gender -- Symptoms -- Complications -- Comorbid Illness -- Smoking -- Secondary Infections -- Laboratory Parameters -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Long Term Complications of COVID-19 -- Ankita Sood1, Bimlesh Kumar1,*, Indu Melkani1, Archit Sood2, Pankaj Prashar1, Anamika Gautam1, Kardam Joshi3 and Dhara Patel3 -- INTRODUCTION -- LONG TERM COMPLICATIONS OF COVID-19 -- COMPLICATIONS OF COVID-19 IN VARIOUS DISEASES -- Diabetes Mellitus (DM) -- Hematological Complications -- Cardiovascular Diseases -- Central Nervous System Complications -- Viral Encephalitis -- Infectious Toxic Encephalopathy and Cerebrovascular Disease -- Chronic Kidney Disease (CKD) -- Asthma and Respiratory Disorders -- Rheumatoid Arthritis (RA) -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Vaccine Development -- Priya Sharma1,#, Shivani Joshi1,#, Aishwarya Joshi1, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: VACCINE DEVELOPMENT -- COVID-19 VACCINE DEVELOPMENT: MODULATING THE HOST IMMUNE SYSTEM -- TYPES OF VACCINES AND THEIR CHARACTERISTICS -- Live-attenuated Virus and Inactivated Whole Virus Vaccines -- Subunit Vaccines -- Vaccines Based on Virus-like Particles (VLPs) -- Viral Vector-based Vaccines -- DNA Vaccines -- NOVEL APPROACHES: USAGE OF MULTIDISCIPLINARY FIELDS -- Serum Albumin Strategy -- Natural Product (Plant) Based Technology -- Nanotechnology and Material Science -- mRNA Based Approaches -- ANIMAL MODELS TO TEST THE IMMUNOGENIC POTENTIAL OF CANDIDATE VACCINE ANTIGENS -- Animal Models Currently in Practice -- Humanized Mice Models -- Novel Approach of Using Zebrafish (Their Advantages) -- CURRENT STATUS OF VACCINE DEVELOPMENT. , BENCH TO BEDSIDE: OBSTACLES AND OUTCOMES -- Lessons from Previous Vaccine Development -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Future of COVID-19 Treatment -- Sahil Arora1,#, Manvendra Kumar1,#, Gaurav Joshi1,* and Raj Kumar1,* -- INTRODUCTION -- DRUGS AFFECTING VIRAL REPLICATION AND TRANSLATION IN COVID-19 DISEASE -- DRUGS INTERFERING WITH INFLAMMATION AND OVERCOMING CYTOKINE STORM IN COVID-19 DISEASE -- ANTICANCER DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- ANTIPARASITIC, ANTIPROTOZOAL, AND ANTIFUNGAL DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- DRUGS AFFECTING THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN COVID-19 -- MISCELLANEOUS -- DISCUSSION AND CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover.

Additional Edition: ISBN 1-68108-807-X

Language: English

Keywords: Electronic books. ; Electronic books.

DOI: 10.2174/97816810880511210101

URL: Click to View

URL: Click to View

UID:

Format: 1 online resource (390 pages)

Edition: 1st ed.

ISBN: 981-5036-36-X

Content: Coronavirus disease 2019 (COVID-19) has affected millions of people across the world. Clinicians and scientists across the globe need all the information of this pandemic on one platform. Today, it is also necessary to find out the association of COVID-19 with various medical comorbidities, and its effect on vulnerable populations that require special medical attention. This information will be helpful for the management of COVID-19. COVID-19: Effects in Comorbidities and Special Populations is a concise and visual reference for information about this viral disease and its relationship with different medical conditions. The book provides comprehensive knowledge covering COVID-19 comorbidities (for example, CVD, Diabetes, lung diseases, etc.), and the incidence in specific groups (for example, children and the elderly). Chapters outline the features and the management of the disease in specific conditions. Key Features: ✓ 12 chapters covering several aspects of COVID-19 management, making this a perfect text book for virologist and medical students ✓ Focused and structured description of different effects of COVID-19 in specific patient groups ✓ Multiple tables and figures which summarizes and highlight important points ✓ Multiple choice questions for learners ✓ Detailed list of references, abbreviations and symbols This book is an essential reference for practicing and training virologists, pulmonologists, medical students and scientists working in research labs, pharmaceutical and biotechnology industries in connection with the control of COVID-19 infectio.

Note: Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- KEY FEATURES: -- List of Contributors -- SARS-CoV-2 and Co-morbidities -- Yara S. Beyh1, Riya Sachdeva2, K. M.Venkat Narayan1 and Manoj Bhasin2,3,* -- HIGHLIGHTS -- INTRODUCTION -- COVID-19: GENERAL CHARACTERISTICS, SUSCEPTIBILITY, AND ASSOCIATION WITH THE IMMUNE SYSTEM -- COVID-19 AND CO-MORBIDITIES -- Diabetes Mellitus -- Obesity and Metabolic Syndrome -- Chronic Kidney Disease -- Cardiovascular Diseases -- Cancer -- Sickle Cell -- Chronic Obstructive Pulmonary Disease -- CONCLUSION -- MULTIPLE CHOICE QUESTIONS -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Diabetes Mellitus and COVID-19 -- Sanjay Kumar Bhadada1,* and Rimesh Pal1 -- HIGHLIGHTS -- INTRODUCTION -- EPIDEMIOLOGY -- PATHOPHYSIOLOGICAL ASSOCIATIONS BETWEEN DIABETES MELLITUS AND COVID-19 -- Advancing Age -- Comorbidities -- Obesity -- Dysregulated Immune System -- Angiotensin-Converting Enzyme 2 (ACE2) And Diabetes Mellitus -- Coagulation -- TWO-WAY INTERACTIONS BETWEEN DIABETES MELLITUS AND COVID-19 -- DOES GLYCEMIC CONTROL BEFORE, AT, AND AFTER ADMISSION PREDICT OUTCOMES IN COVID-19 PATIENTS WITH DIABETES MELLITUS? -- Glycemic Control Before Hospital Admission -- Plasma Glucose At Hospital Admission -- In-Hospital Glycemic Control -- ANTI-DIABETIC MEDICATIONS IN COVID-19 -- CONCLUSION -- MULTIPLE CHOICE QUESTIONS -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Diabetic Foot -- Ashu Rastogi1,* -- HIGHLIGHTS -- INTRODUCTION -- FOOT EXAMINATION AND COVID-19 -- Foot Inspection -- Neurological Assessment -- Vascular Assessment -- DIABETIC FOOT INFECTIONS AND COVID-19 PANDEMIC -- An Easy Guide to Antibiotic Therapy is as Follows -- DFI, COVID-19 AND WAY FORWARD. , CHARCOT FOOT AND COVID-19 -- PREVENTIVE FOOT CARE DURING COVID-19 PANDEMIC -- FOOT CARE IN PATIENTS WITH PRE-EXISTING WOUNDS DURING COVID-19 PANDEMIC -- DRESSING OF FOOT WOUND DURING COVID -19 PANDEMIC -- FOOT CARE FOR DFI DURING COVID-19 -- WHO SHOULD BE HOSPITALIZED FOR FOOT COMPLICATIONS? -- UTILIZATION OF TELE-HEALTH SERVICES FOR DIABETIC FOOT DURING COVID-19 -- PROMOTE SELF CARE (FOOT) DURING COVID-19 -- PRECAUTIONS FOR HEALTH CARE PROVIDERS -- CONCLUSION -- MULTIPLE CHOICE QUESTIONS -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Gastrointestinal and Hepatobiliary Manifestations of COVID-19 -- Rohit Mehtani1 and Sunil Taneja1,* -- HIGHLIGHTS -- INTRODUCTION -- GI TROPISM OF SARS-COV-2 -- GI SYMPTOMATOLOGY -- Relation of GI Symptoms with COVID-19 Severity -- POSSIBILITY OF FECO-ORAL TRANSMISSION OF COVID 19? -- GI HISTOPATHOLOGY OF PATIENTS WITH COVID-19 -- MANAGEMENT OF GI SYMPTOMS IN COVID-19 -- LIVER INJURY WITH COVID-19 -- MECHANISMS OF LIVER INJURY -- Role of ACE 2 and Serine protease -- Direct Cytopathic Effects -- Cytokine Storm -- Ischaemic Hepatitis And Drug Toxicity -- HISTOPATHOLOGICAL FINDINGS IN THE LIVER -- COVID-19 IN PATIENTS WITH CHRONIC LIVER DISEASE -- LIVER FAILURE DUE TO COVID-19 -- LIVER TRANSPLANTATION AND COVID-19 -- GI ENDOSCOPY PRACTICES DURING COVID-19 PANDEMIC -- CONCLUSION -- MULTIPLE CHOICE QUESTIONS -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Cardiovascular Manifestations -- Ganesh Kasinadhuni1, Vineela Chikkam2, Parminder Singh1 and Rajesh Vijayvergiya1,* -- HIGHLIGHTS -- INTRODUCTION -- Biology of SARS-CoV-2 -- Pathophysiology of SARS-Cov-2 Related Tissue Injury -- ACE2 -A link to Cardiovascular (CV) Injury -- COVID-19 and Cardiovascular Disease (CVD). , COVID-19 and Cardiovascular (CV) Effects -- ACUTE CARDIOVASCULAR (CV) MANIFESTATIONS -- Acute Cardiac Injury and Myocarditis -- Management -- Cardiac Arrhythmias -- Management -- Acute Coronary Syndromes (ACS) -- Management -- Venous Thromboembolism (VTE) -- Management -- Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors And Cardiovascular Outcomes In COVID-19 Illness -- Antiviral Drugs and their Cardiovascular Effects -- Hydroxychloroquine (HCQ) and Azithromycin -- Lopinavir-ritonavir -- Long-term Cardiovascular Effects - Long COVID -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Hematological Manifestations -- Niranjan Shiwaji Khaire1, Nishant Jindal1 and Pankaj Malhotra1,* -- HIGHLIGHTS -- INTRODUCTION -- COVID-19 AND HEMATOLOGICAL MANIFESTATIONS -- Total Leukocyte Count and Differential Count -- a. Lymphopenia -- b. Neutrophilic Leukocytosis -- c. Thrombocytosis and Thrombocytopenia -- d. Composite Variables: NLR and PLR Ratios -- e. What is the Clinical Utility of Following these Alterations in the CBC? -- Coagulation System -- COVID-19 Coagulopathy -- THROMBOSIS AND THROMBOEMBOLISM -- The Large vessel Thrombosis (Venous thromboembolism and Pulmonary Thromboembolism) -- Large Vessel Thrombosis (Arterial, extracorporeal circuit thrombosis) -- Microvascular Thrombosis and Autopsy data on thrombosis -- Pathophysiology of VTE and Immunothrombosis in COVID-19 -- Acute Illness -- Patient-related -- SARS-CoV2 Related -- COVID-19 VS. NON-COVID-19 ILLNESS -- TREATMENT IMPLICATIONS -- CONCLUSION -- MULTIPLE CHOICE QUESTIONS -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 And Chronic Kidney Diseases -- Vikas Makkar1,*, Sudhir Mehta1, Suman Sethi1, Simran Kaur1 and P.M. Sohal1. , INTRODUCTION: AKI/ACUTE ON CKD IN COVID-19 -- Prevalence of AKI in COVID-19 -- Pathophysiology of Acute Kidney Injury in COVID-19 -- Mechanisms -- Systemic Effects -- Fluid Imbalance -- Congestion of Renal Vein -- Rhabdomyolysis -- Superimposed Infections -- Cytokine Storm -- Pathogenesis of AKI in CRS -- Pro-inflammatory Cytokines -- Activation-induced Cell Death -- Activation of Procoagulation Pathways -- Complement System Activation -- Heme-Mediated Pathology -- Systemic Endothelial Injury -- Organ Crosstalk -- Lung-Kidney Axis and Crosstalk -- Mechanism of Lung-Kidney Crosstalk -- Renal Medullary Hypoxia -- ROLE OF ACE2 IN THE PATHOGENESIS OF RENAL INJURY -- Site of ACE2 in Lungs/Kidneys -- Entry of Virus into the Cell -- Priming and Role of TMPRSS2 -- Angiotensin II -- DIRECT CYTOPATHIC EFFECT -- Clinical Presentation -- Incidence of AKI -- Timing & -- Severity of AKI -- Predictors of AKI -- Kidney Abnormalities -- Outcome -- Renal Histopathology -- COVAN -- MANAGEMENT OF AKI -- RECOGNITION, MONITORING, AND DIAGNOSIS OF AKI IN COVID-19 PATIENTS -- Renal Replacement Therapy -- Preferred Treatment Modality for AKI in COVID-19 Pandemic -- Other Extracorporeal Therapies -- CKD IN COVID-19 -- Management of Glomerular Diseases During COVID-19 Pandemic -- IMMUNOSUPPRESSIVE TREATMENT IN VARIOUS KIDNEY DISEASES DURING COVID-19 PANDEMIC -- Antiviral Therapy for Covid-19 -- Remdesivir -- Hydroxychloroquine -- Lopinavir-Ritonavir and Darunavir-Cobicistat -- High-Dose Steroids -- Tocilizumab and other Anti-Interleukin (IL)-6/IL-6R Monoclonal Antibodies (e.g., Sarilumab) -- Intravenous Immunoglobulins -- Ivermectin -- USE OF ARBS DURING PANDEMIC -- Paradoxical Effect of ACE2 Modulation in COVID-19 Outcome -- COVID- 19 AND DIALYSIS -- COVID 19 AND HEMODIALYSIS -- Dialysis Patients and Dialysis Facilities. , Disinfection and Disposal Practices in the Dialysis Unit -- Bleach Solution -- Alcohol-Based Solutions -- CRRT -- CRRT Dosing -- Modifications to CRRT for COVID- 19 Positive -- OTHER EXTRACORPOREAL THERAPY FOR COVID-19 -- ECOS Modifications in Relation to COVID-19 -- Extracorporeal Therapies in CRS -- The Rationale of Using CytoSorb Therapy in Critically ill COVID-19 Patients -- CytoSorb Therapy - Experience in Rx of COVID-19 -- Recommendations for Anti-Cytokine Storm Therapy -- Recommendations from Italy -- Recommendations from Italy -- Recommendations from Panama -- Practical Recommendations During COVID Pandemic -- PERITONEAL DIALYSIS -- Role of Acute PD in the Management of CoV-AKI -- Advantages -- Patients Already on CAPD -- New Patient Planned for CAPD -- Coronavirus Disease 2019-Specific Concerns for PD -- COVID 19 AND KIDNEY TRANSPLANTATION -- Transplant Activity Report during this Pandemic -- Data Published from India -- Transmission of COVID-19 Infection During Transplantation -- Selection Criteria for Donor/Recipient During COVID-19 Pandemic -- Deceased Donors -- Clinical Criteria (Prasad et al., 2020a). -- Epidemiological Criteria -- Living Related Transplants -- Transplantation Recipients -- Post-Transplant Follows up Measures -- Precautions for Personnel Working in the Program -- Clinical Presentation, Disease Course, or outcomes in the Transplant Recipient -- Evidence and Experiences from Data Published -- Management of Immunosuppression During COVID-19 Pandemic -- MULTIPLE CHOICE QUESTIONS -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Pulmonary Diseases -- Kuruswamy Thurai Prasad1,* -- HIGHLIGHTS -- INTRODUCTION -- PATHOPHYSIOLOGY -- TRANSMISSION AND RISK FACTORS -- PULMONARY INVOLVEMENT IN COVID-19 -- Clinical Features -- Laboratory Abnormalities. , Radiology.

Additional Edition: Print version: Bhadada, Sanjay Kumar COVID-19: Effects in Comorbidities and Special Populations Bielefeld : Bentham Science Publishers,c2022 ISBN 9789815036374

Language: English